Fintel reports that on November 13, 2024, Leerink Partners downgraded their outlook for 908 Devices (NasdaqGM:MASS) from ...

(Bloomberg) -- Leerink Partners, the health-care advisory firm, has continued a recent recruitment drive with hires from ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from ...

Analyst Mani Foroohar of Leerink Partners maintained a Buy rating on RegenXBio (RGNX – Research Report), boosting the price target to $38.00. Don't Miss our Black Friday Offers: Discover the latest ...

Leerink Partners analyst Mani Foroohar maintained a Hold rating on CureVac (CVAC – Research Report) on November 12. The company’s ...

Research analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Ardent Health Partners in a ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Industry Veterans Grant Curry and Jason Truman Join Leerink Partners. BOSTON, Nov. 14, 2024 /PRNewswire/ -- Leerink Partners, a leading investment bank specializing in healthcare, announced today ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

Fintel reports that on November 12, 2024, Leerink Partners upgraded their outlook for Bristol-Myers Squibb (WBAG:BMYS) from Market Perform to Outperform. There are 3,419 funds or institutions ...